Pfizer Inc: A behemoth in the making - Views on News from Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

Pfizer Inc: A behemoth in the making

Jul 16, 2002

Call it a lesson in how sheer size can make a strategic difference in the pharma industry. In yet another display of company’s aggressiveness to stay on top, Pfizer Inc has declared a mega buyout of Pharmacia for US$ 60 bn in an all-stock deal. It was only in early 2000 that the company bought over Warner Lambert for US$ 90 bn, to snatch the top position in the global pharma industry. No wonder, the industry is in for another round of consolidation with patent expirations and severe generic competition giving a tough time to Big Boys. “We have never been in a better position”, was a recent statement by Pfizer’s CEO, Mr. McKinnell. While most of the global pharma giants like Merck, Schering and Bristol had warned investors of low or flat growth, Pfizer went ahead and promised a 20% or more growth for FY02.

Globally, Pfizer, which is the biggest US drug marketing company, will now have a tremendous marketing clout with more than 13,000 representatives in the US. This would make Pfizer possibly the strongest pharma company on all major counts viz, research strength, marketing capabilities and a strong multi-billion dollar products portfolio. The combined entity would have a whopping US$ 7 bn research budget (this is approximately twice the size of Indian pharma industry). The combined entity would have sales of almost US$ 47 bn, almost twice the sales of its nearest competitor GlaxoSmithKline.

Most importantly, Pfizer Inc would gain control over Pharmacia’s multi-billion arthritis pain drugs namely Celebrex and Bextra, each with sales of more US$ 3 bn. Post the acquisition, Pfizer Inc. would have 8 multi-billion dollar products in its portfolio, the biggest and most enviable in the global pharma industry.

Pfizer Inc’s- Multi-billion dollar products
Product Indication 2000 Revenues
(US$ bn)
Year of
Patent Expiry
Diflucan Fungal Infections 1 2004
Zoloft Depression 2.1 2005
Zithromax Bacterial Infections 1.4 2005
Lipitor High Cholesterol 5 2006
Norvasc Hyper tension, Angina 3.4 2007
Viagra Erectile dysfunction 1.3 2011
Celebrex Arthritis 3 2013
Bextra Arthritis 3 NA

In India, the acquisition is likely to push Pfizer India to the fourth largest position in the domestic pharma industry. Pharmacia’s Indian operations consist of two entities viz; Pharmacia India Pvt. Ltd and Pharmacia Healthcare Ltd. Pharmacia Healthcare is erstwhile Abbott Laboratories, which Pharmacia acquired in Jan’02. The following conclusions can be drawn of the global merger for India:

  • Pfizer India has recently completed integration of Parke Davis India into itself. Post the integration, the merged entity’s combined sales is expected to be Rs 5.7 bn. Pharmacia Healthcare Ltd has annual sales of Rs 896 m. However, the margins of Abbott Laboratories don’t compare favorably with that of Pfizer-Parke Davis and hence there is unlikely to be a substantial addition to its bottom line. It is likely that Pfizer may have to rework another restructuring exercise based on its brand portfolio. Pfizer’s Inc’s policy of product introductions is very conservative and there could be a case where the company might decide to withdraw some Pharmacia’s products.

    Year – FY02 (Rs m) Pfizer Parke Davis Pharmacia India
    (erstwhile Abbott India)
    Consolidated*
    Net Sales 3,206 2,134 896 6,236
    Operating Margins (%) 7.20% 14.00% 6.00% 9.40%
    Net Profit 475 250 12 737
    (*- Excl. Pharmacia India Pvt.Ltd)

  • The structure of Pfizer Inc’s operation in India is likely to become complex. While Pfizer and Warner Lambert already have a subsidiary each operating in India, Pharmacia would add another one to the bouquet.

  • Pfizer India will have to come out with an open offer for the minority shareholders of the erstwhile Abbott Laboratories, comprising 25% of the equity. Considering the last six-month average prices is considerably higher than the current market price, Abbott shareholders stand to gain.

Equitymaster requests your view! Post a comment on "Pfizer Inc: A behemoth in the making". Click here!

  

More Views on News

PFIZER Announces Quarterly Results (3QFY21); Net Profit Up 1.6% (Quarterly Result Update)

Feb 10, 2021 | Updated on Feb 10, 2021

For the quarter ended December 2020, PFIZER has posted a net profit of Rs 1 bn (up 1.6% YoY). Sales on the other hand came in at Rs 6 bn (up 10.3% YoY). Read on for a complete analysis of PFIZER's quarterly results.

PFIZER Announces Quarterly Results (2QFY21); Net Profit Down 14.8% (Quarterly Result Update)

Nov 4, 2020 | Updated on Nov 4, 2020

For the quarter ended September 2020, PFIZER has posted a net profit of Rs 1 bn (down 14.8% YoY). Sales on the other hand came in at Rs 6 bn (up 5.0% YoY). Read on for a complete analysis of PFIZER's quarterly results.

5 Indian Pharma Companies Riding the Vaccination Wave (Views On News)

Sep 3, 2021

These companies are likely to benefit the most from Covid-19 vaccines.

Apollo Hospitals' Shares Rally Over 5%, Hit Record-High on Strong Results (Views On News)

Aug 16, 2021

The company reported a 73% YoY increase in revenue driven by an uptick in the hospital and pharmacy business.

J B Chemicals & Pharma's Decent Performance Puts Stock in Focus (Views On News)

Aug 13, 2021

The company seeks to expand the market for prescription lozenges with new launches this year.

More Views on News

Most Popular

Sansera Engineering IPO: Key Points to Consider (Views On News)

Sep 8, 2021

This IPO is a pure OFS and the company is looking to raise Rs 12.8 bn at the upper price band of Rs 744.

5 Stocks that Turned Rs 1 Lakh into Rs 1 Crore (Views On News)

Sep 7, 2021

Patience is one of the biggest virtues you need to have if you want to become a crorepati in the stock market.

The Top Stocks to Sell in this Bull Market (Profit Hunter)

Sep 8, 2021

When I saw the list of so-called 'value stocks' published by a leading brokerage, my worst fears came true.

5 Indian Companies that are Leading the AI Race (Views On News)

Sep 9, 2021

During the pandemic, India reported the highest increase in the use of AI at 45% compared to other major economies. AI has potential to add US$90 bn to the Indian economy by 2025.

How to Create a Second Income from Trading (Profit Hunter)

Sep 10, 2021

My trading system that works in all kinds of markets.

More

Become A Smarter Investor
In Just 5 Minutes

Multibagger Stock Guide 2021
Get our special report Multibagger Stocks Guide (2021 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

PFIZER SHARE PRICE


Sep 17, 2021 (Close)

TRACK PFIZER

PFIZER - ADCOCK INGRAM COMPARISON

COMPARE PFIZER WITH

MARKET STATS